by Single cell genome sequencing allows analysis of DNA, RNA or proteins of individual cells. This helps understand cellular heterogeneity in tissues and tumors at an unprecedented resolution. Traditional bulk sequencing techniques provide average information from millions of cells, masking cell-to-cell variations. Single cell genome sequencing deconvolutes complex tissue into constituent cell types and states. It helps study developmental processes, track immune system responses, characterize circulating tumor cells and monitor cell regeneration mechanisms.
The global Single Cell Genome Sequencing Market is estimated to be valued at US$ 2.28 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the single cell genome sequencing market is the development of platforms that enable whole genome amplification of single cells. Current techniques depend on serial amplification of DNA from a single cell using PCR or WGA. However, this amplification is biased and non-uniform, skewing analysis. Companies are developing novel methods to unbiasedly and uniformly amplify entire genomes from single cells. This will improve resolution and accuracy of single cell sequencing studies. Another trend is integration of multi-omics capabilities on single cell sequencing systems. Vendors are launching platforms that can simultaneously analyze genomic, epigenomic and transcriptomic profiles of individual cells. This multi-dimensional single cell analysis holds potential to gain novel biological insights at an unprecedented resolution.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as single cell genome sequencing market involves huge capital expenditure and highly technical knowledge. However, government funding and technological advancement lowers the entry barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate. Buyers have options to choose from established as well as emerging players in the market.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitute components. Suppliers are dependent on key players for revenue generation.
Threat of new substitutes: The threat of new substitutes is high due to continuous product innovation. Emerging technologies like DNA sequencing tools pose threat to existing products.
Competitive rivalry: The competitive rivalry is high among global players to gain maximum market share through expansion and new product launches.
Key Takeaways
The Global Single Cell Genome Sequencing Market Size is expected to witness high growth over the forecast period. The global Single Cell Genome Sequencing Market is estimated to be valued at US$ 2.28 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030.
North America is currently dominating the market due to presence of key players and rising R&D activities for genome sequencing. The Asia Pacific region is expected to grow at fastest rate owing to increasing healthcare expenditure and clinical trials in countries like China and India.
Key players operating in the single cell genome sequencing market are 10x Genomics, Fluidigm Corporation, Bio-Rad Laboratories, Bruker, Illumina, Fludigim Corporation, Qiagen and Novogene Corporation. These players are focusing on new product launches and innovations to gain competitive advantage in the market.
10x Genomics launched single cell multiome ATAC + gene expression solution to enable joint profiling of chromatin accessibility and gene expression from the same single cell. Illumina acquired BlueBee to strengthen informatics capabilities for single cell and spatial multi-omics applications.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
